Theradiag announces CE marketing for i-Tracker® test kits

Mar 10, 2020

On 10 March 2020, Theradiag announced CE marking for its first four i-Tracker® test kits. The Infliximab, i-Tracker® Anti-Infliximab, i-Tracker® Adalimumab and i-Tracker® Anti-Adalimumab are designed to improve individual therapeutic drug monitoring and to allow clinicians to adjust treatment immediately.

Print Page Mail Article